

DAFTAR PUSTAKA

- Adiningsih, S., Purba, D. A., Natalia, E. I., Wike, I., Fitriana, E., Widiyanti, M., & Hutapea, H. M. L. (2021). Gambaran Terapi Antiretroviral Pada Orang Dengan HIV/ AIDS di Manokwari, Fak-Fak dan Kota Sorong, Papua Barat. *Buletin Penelitian Kesehatan*, 49(1), 21–28. <https://doi.org/10.22435/bpk.v49i1.3668>
- Almerico, A. M., Tutone, M., & Lauria, A. (2008). Docking and multivariate methods to explore HIV-1 drug-resistance: A comparative analysis. *Journal of Computer-Aided Molecular Design*, 22(5), 287–297. <https://doi.org/10.1007/s10822-008-9186-7>
- Annan, A., Raiss, N., Lemrabet, S., Elomari, N., Elmir, E. H., Filali-Maltouf, A., Medraoui, L., & Oumzil, H. (2024). Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study. *International Journal of Immunopathology and Pharmacology*, 38, 03946320241231465. <https://doi.org/10.1177/03946320241231465>
- Apetrei, C., Hahn, B., Rambaut, A., Wolinsky, S., Brister, J. R., Keele, B., & Faser, C. (Eds.). (2023). *HIV sequence compendium 2021* (LA-UR-23-22840). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory.
- Appiah, P., Gbassana, G., Adusei-Poku, M., Obeng, B. M., Duedu, K. O., & Sagoe, K. W. C. (2024). Genetic landscape for majority and minority HIV-1 drug resistance mutations in antiretroviral therapy naive patients in Accra, Ghana. *Heliyon*, 10(12), e33180. <https://doi.org/10.1016/j.heliyon.2024.e33180>
- Barnard, J. P., Huber, K. D., & Sluis-Cremer, N. (2019). Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase. *Antimicrobial Agents and Chemotherapy*, 63(8), e00676-19. <https://doi.org/10.1128/AAC.00676-19>
- Baroroh, S.Si., M.Biotek., U., Muscifa, Z. S., Destiarani, W., Rohmatullah, F. G., & Yusuf, M. (2023). Molecular interaction analysis and visualization of

- protein-ligand docking using Biovia Discovery Studio Visualizer. *Indonesian Journal of Computational Biology (IJCB)*, 2(1), 22. <https://doi.org/10.24198/ijcb.v2i1.46322>
- Butt, L., Morin, J., Numbery, G., Peyon, I., & Goo, A. (2010). Stigma dan HIV/AIDS di wilayah pegunungan papua. *Canada: Pusat Studi Kependudukan*.
- Dallakyan, S., & Olson, A. J. (2015). Small-molecule library screening by docking with PyRx. In *Methods in Molecular Biology* (Vol. 1263, pp. 243–250). Humana Press. https://doi.org/10.1007/978-1-4939-2269-7_19
- Delgado, J., Radusky, L. G., Cianferoni, D., & Serrano, L. (2019). FoldX 5.0: Working with RNA, small molecules and a new graphical interface. *Bioinformatics*, 35(20), 4168–4169. <https://doi.org/10.1093/bioinformatics/btz184>
- Delviks-Frankenberry, K. A., Lengruber, R. B., Santos, A. F., Silveira, J. M., Soares, M. A., Kearney, M. F., Maldarelli, F., & Pathak, V. K. (2013). Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance. *Virology*, 435(2), 433–441. <https://doi.org/10.1016/j.virol.2012.09.021>
- Dimmock, N. J., Easton, A. J., & Leppard, K. N. (2007). *Introduction to modern virology* (6th ed). Blackwell Pub.
- Faraci, G., Park, S. Y., Dubé, M. P., & Lee, H. Y. (2023). Full-spectrum HIV drug resistance mutation detection by high-resolution complete pol gene sequencing. *Journal of Clinical Virology*, 164, 105491. <https://doi.org/10.1016/j.jcv.2023.105491>
- Fiebig, U., Altmann, B., Hauser, A., Koppe, U., Hanke, K., Gunsenheimer-Bartmeyer, B., Bremer, V., Baumgarten, A., & Bannert, N. (2023). Transmitted drug resistance and subtype patterns of viruses from reported new HIV diagnoses in Germany, 2017–2020. *BMC Infectious Diseases*, 23(1), 673. <https://doi.org/10.1186/s12879-023-08649-3>

- Fields, B. N. (2007). *Fields virology* (Vol. 1). Lippincott Williams & Wilkins.
- Gao, W., Zhou, G., Li, M., Wang, P., Li, J., & Deng, R. (2024). HIV drug resistance: Analysis of viral genotypes and mutation loci in people living with HIV in Chongqing, China (2016–2023). *AIDS Research and Therapy*, *21*(1), 62. <https://doi.org/10.1186/s12981-024-00646-z>
- Giacomelli, A., Lai, A., Franzetti, M., Maggiolo, F., Di Giambenedetto, S., Borghi, V., Francisci, D., Magnani, G., Pecorari, M., Monno, L., Vicenti, I., Lepore, L., Lombardi, F., Paolucci, S., & Rusconi, S. (2019). No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference. *Antiviral Research*, *172*, 104635. <https://doi.org/10.1016/j.antiviral.2019.104635>
- Gifford, R. J., Liu, T. F., Rhee, S.-Y., Kiuchi, M., Hue, S., Pillay, D., & Shafer, R. W. (2009). The calibrated population resistance tool: Standardized genotypic estimation of transmitted HIV-1 drug resistance. *Bioinformatics*, *25*(9), 1197–1198. <https://doi.org/10.1093/bioinformatics/btp134>
- Green, C. W. (2016). *Pengobatan Untuk AIDS: Ingin Mulai?*
- Hariastuti, N. I., Wibowo, H. A., Adam, K., Subangkit, N., Kipuw, N. L., & Roselinda, N. (2017). Potensi Resistensi Virus HIV-1 terhadap Terapi Anti Retroviral (ART) pada Pasien Voluntary Counseling and Testing (VCT) di Beberapa Kota di Indonesia. *Media Penelitian dan Pengembangan Kesehatan*, *26*(3), 151–156. <https://doi.org/10.22435/mpk.v26i3.4610.151-156>
- Hasanshahi, Z., Hashempour, A., Moayedi, J., Musavi, Z., Rezaei, B., Dehghani, B., & Ghasabi, F. (2023). Naturally Occurring Mutations in HIV-1 Protease Gene Among People Living With HIV. *ACTA MEDICA IRANICA*. <https://doi.org/10.18502/acta.v61i3.12736>
- Hauser, A., Goldstein, F., Reichmuth, M. L., Kouyos, R. D., Wandeler, G., Egger, M., & Riou, J. (2022). Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian

- evidence synthesis. *Journal of Clinical Epidemiology*, 148, 135–145.
<https://doi.org/10.1016/j.jclinepi.2022.02.005>
- Hong, H., Tang, C., Liu, Y., Jiang, H., Fang, T., & Xu, G. (2023). HIV-1 drug resistance and genetic transmission network among newly diagnosed people living with HIV/AIDS in Ningbo, China between 2018 and 2021. *Virology Journal*, 20(1), 233. <https://doi.org/10.1186/s12985-023-02193-x>
- Hutapea, H. M. L., Kridaningsih, T. N., Prasetyo, K. H., & Antwi, M. B. (2021). Viral load as a risk factor of reverse transcriptase inhibitor drug resistance mutation in antiretroviral-treated people living with HIV/AIDS. *Universa Medicina*, 40(3), 243–253.
<https://doi.org/10.18051/UnivMed.2021.v40.243-253>
- Hwang, C., Lai, M.-T., & Hazuda, D. (2020). Rational Design of Doravirine: From Bench to Patients. *ACS Infectious Diseases*, 6(1), 64–73.
<https://doi.org/10.1021/acsinfecdis.9b00178>
- James, C., Preininger, L., & Sweet, M. (2012). Rilpivirine: A second-generation nonnucleoside reverse transcriptase inhibitor. *American Journal of Health-System Pharmacy*, 69(10), 857–861. <https://doi.org/10.2146/ajhp110395>
- Kemenkes, R. I. (2011). Pendoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada orang Dewasa. *Jakarta: Kementerian Kesehatan Republik Indonesia*.
- Kemenkes, R. I. (2014). Peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2014 tentang Pedoman Pengobatan Antiretroviral. *Jakarta: Kementerian Kesehatan Republik Indonesia*.
- Kementerian Kesehatan Republik Indonesia. (2024). *Laporan eksekutif perkembangan HIV AIDS dan penyakit infeksi menular seksual (PIMS) semester I tahun 2024*. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Khairunisa, S. Q., Megasari, N. L. A., Indriati, D. W., Kotaki, T., Natalia, D., Nasronudin, & Kameoka, M. (2020). Identification of HIV-1 subtypes and drug resistance mutations among HIV-1-infected individuals residing in

Pontianak, Indonesia. *Germs*, 10(3), 174–183.
<https://doi.org/10.18683/germs.2020.1203>

Kiang, T. K. L., Wilby, K. J., & Ensom, M. H. H. (Eds.). (2016). *Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs*. Springer Singapore. <https://doi.org/10.1007/978-981-10-2113-8>

Levinson, W. (2016). *Review of medical microbiology and immunology* (Fourteenth edition). McGraw-Hill Education.

Liu, T. F., & Shafer, R. W. (2006). Web resources for HIV type 1 genotypic-resistance test interpretation. *Clinical Infectious Diseases*, 42(11), 1608–1618. <https://doi.org/10.1086/503914>

Luk, C., Wu, J., & Njoo, E. (2022). Homology modeling of clinically-relevant rilpivirine-resistant HIV-RT variants identifies novel rilpivirine analogs with retained binding affinity against NNRTI-resistant HIV mutations. *Journal of Emerging Investigators*. <https://doi.org/10.59720/21-071>

Mamrosh, J. L., David-Fung, E.-S., Korber, B. T. M., Brander, C., Barouch, D., de Boer, R., Haynes, B. F., Klasse, P. J., Koup, R., Peters, B., Seaman, M., & Walker, B. D. (Eds.). (2024). *HIV molecular immunology* (LA-UR-24-32444). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory.

Menéndez-Arias, L., Betancor, G., & Matamoros, T. (2011). HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors. *Antiviral Research*, 92(2), 139–149. <https://doi.org/10.1016/j.antiviral.2011.08.020>

Miceli, L., Teixeira, V., Castro, H., Rodrigues, C., Mello, J., Albuquerque, M., Cabral, L., De Brito, M., & De Souza, A. (2013). Molecular Docking Studies of Marine Diterpenes as Inhibitors of Wild-Type and Mutants HIV-1 Reverse Transcriptase. *Marine Drugs*, 11(11), 4127–4143. <https://doi.org/10.3390/md11114127>

- Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *Journal of Computational Chemistry*, 30(16), 2785–2791. <https://doi.org/10.1002/jcc.21256>
- Mukhatayeva, A., Mustafa, A., Dzissyuk, N., Issanov, A., Mukhatayev, Z., Bayserkin, B., Vermund, S. H., & Ali, S. (2022). Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan. *Scientific Repots*, 12(1), 17195. <https://doi.org/10.1038/s41598-022-22163-7>
- Namasivayam, V., Vanangamudi, M., Kramer, V. G., Kurup, S., Zhan, P., Liu, X., Kongsted, J., & Byrareddy, S. N. (2019). The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic. *Journal of Medicinal Chemistry*, 62(10), 4851–4883. <https://doi.org/10.1021/acs.jmedchem.8b00843>
- Nastri, B. M., Pagliano, P., Zannella, C., Folliero, V., Masullo, A., Rinaldi, L., Galdiero, M., & Franci, G. (2023). HIV and Drug-Resistant Subtypes. *Microorganisms*, 11(1), 221. <https://doi.org/10.3390/microorganisms11010221>
- Nurjannah, Jayanti, S., Tanoerahardjo, F. S., Al Musyahadah, U. S., Sukowati, C. H. C., & Massi, M. N. (2024). Major Drug Resistance Mutations on Reverse Transcriptase Gene in Human Immunodeficiency Virus Type-1 in Indonesia: A Systematic Review. *Current HIV/AIDS Reports*, 21(2), 31–39. <https://doi.org/10.1007/s11904-023-00687-5>
- Ozvoldik, K., Stockner, T., & Krieger, E. (2023). YASARA Model–Interactive Molecular Modeling from Two Dimensions to Virtual Realities. *Journal of Chemical Information and Modeling*, 63(20), 6177–6182. <https://doi.org/10.1021/acs.jcim.3c01136>
- Pang, X., Lu, H., He, Q., Tang, K., Ma, J., Chen, S., Huang, J., Fang, N., Xie, H., Lan, G., & Liang, S. (2024). Emergence of HIV-1 drug resistance mutations among children and adolescents undergoing prolonged antiretroviral

therapy in Guangxi. *Journal of Global Antimicrobial Resistance*, 37, 208–213. <https://doi.org/10.1016/j.jgar.2024.03.013>

Parczewski, M., Urbańska, A., Maciejewska, K., Witak-Jędra, M., & Leszczyszyn-Pynka, M. (2014). Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland. *Journal of the International AIDS Society*, 17(1), 18929. <https://doi.org/10.7448/IAS.17.1.18929>

Parija, S. C. (2014). *Textbook of Microbiology & Immunology* (2nd ed). Elsevier Health Sciences APAC.

Pham, H. T., Xiao, M. A., Principe, M. A., Wong, A., & Mesplède, T. (2020). Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection. *Drugs in Context*, 9, 1–11. <https://doi.org/10.7573/dic.2019-11-4>

Pirkl, M., Büch, J., Friedrich, G., Böhm, M., Turner, D., Degen, O., Kaiser, R., & Lengauer, T. (2024). Geno2pheno: Recombination detection for HIV-1 and HEV subtypes. *NAR Molecular Medicine*, 1(1). <https://doi.org/10.1093/narmme/ugae003>

Rhee, S. Y., Kantor, R., Katzenstein, D. A., Camacho, R., Morris, L., Sirivichayakul, S., Jorgensen, L., Brigido, L. F., Schapiro, J. M., & Shafer, R. W. (2006). HIV-1 pol mutation frequency by subtype and treatment experience: Extension of the HIVseq program to seven non-B subtypes. *AIDS*, 20(5), 643–651. <https://doi.org/10.1097/01.aids.0000216363.36786.2b>

Rhee, S.-Y., Gonzales, M. J., Kantor, R., Betts, B. J., Ravela, J., & Shafer, R. W. (2003). Human immunodeficiency virus reverse transcriptase and protease sequence database. *Nucleic Acids Research*, 31(1), 298–303. <https://doi.org/10.1093/nar/gkg100>

Saag, M. S., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Thompson, M. A., Sax, P. E., Smith, D. M., Benson, C. A., Buchbinder, S. P., Del Rio, C., Eron, J. J., Fätkenheuer, G., Günthard, H. F., Molina, J.-M., Jacobsen, D. M., & Volberding, P. A. (2020). Antiretroviral Drugs for Treatment and Prevention

- of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society–USA Panel. *JAMA*, 324(16), 1651. <https://doi.org/10.1001/jama.2020.17025>
- Sarafianos, S. G., Marchand, B., Das, K., Himmel, D. M., Parniak, M. A., Hughes, S. H., & Arnold, E. (2009). Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and Inhibition. *Journal of Molecular Biology*, 385(3), 693–713. <https://doi.org/10.1016/j.jmb.2008.10.071>
- Sarafianos, S. G., Marchand, B., Das, K., Himmel, D. M., Parniak, M. A., Hughes, S. H., & Arnold, E. (2009). Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and Inhibition. *Journal of Molecular Biology*, 385(3), 693–713. <https://doi.org/10.1016/j.jmb.2008.10.071>
- Schrödinger, LLC. (n.d.). The PyMOL molecular graphics system (Version 3.0) [Computer software]. <https://pymol.org>
- Seal, A., Aykkal, R., & Ghosh, M. G. (2011). Docking study of HIV-1 reverse transcriptase with phytochemicals. *Bioinformation*, 5(10), 430–439. <https://doi.org/10.6026/97320630005430>
- Shafer, R. W. (2006). Rationale and uses of a public HIV drug-resistance database. *Journal of Infectious Diseases*, 194(Suppl 1), S51–S58. <https://doi.org/10.1086/505356>
- Shafer, R. W., Jung, D. R., & Betts, B. J. (2000). Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. *Nature Medicine*, 6(11), 1290–1292. <https://doi.org/10.1038/81407>
- Shchemelev, A. N., Semenov, A. V., Ostankova, Yu. V., Zueva, E. B., Valutite, D. E., Semenova, D. A., Davydenko, V. S., & Totolian, A. A. (2022). Genetic diversity and drug resistance mutations of HIV-1 in Leningrad Region. *Journal of Microbiology, Epidemiology and Immunobiology*, 99(1), 28–37. <https://doi.org/10.36233/0372-9311-216>

- Singh, A. K., & Das, K. (2022). Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies. *Viruses*, 14(5), 1027. <https://doi.org/10.3390/v14051027>
- Singh, A. K., Kumar, A., Arora, S., Kumar, R., Verma, A., Khalilullah, H., Jaremko, M., Emwas, A., & Kumar, P. (2024). Current insights and molecular docking studies of HIV-1 reverse transcriptase inhibitors. *Chemical Biology & Drug Design*, 103(1), e14372. <https://doi.org/10.1111/cbdd.14372>
- Singh, K., Marchand, B., Kirby, K. A., Michailidis, E., & Sarafianos, S. G. (2010). Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase. *Viruses*, 2(2), 606–638. <https://doi.org/10.3390/v2020606>
- Sivay, M. V., Maksimenko, L. V., Nalimova, T. M., Nefedova, A. A., Osipova, I. P., Kriklivaya, N. P., Gashnikova, M. P., Ekushov, V. E., Totmenin, A. V., Kapustin, D. V., Pozdnyakova, L. L., Skudarnov, S. E., Ostapova, T. S., Yaschenko, S. V., Nazarova, O. I., Shevchenko, V. V., Ilyina, E. A., Novikova, O. A., Agafonov, A. P., & Gashnikova, N. M. (2024). HIV drug resistance among patients experiencing antiretroviral therapy failure in Russia, 2019–2021. *International Journal of Antimicrobial Agents*, 63(2), 107074. <https://doi.org/10.1016/j.ijantimicag.2023.107074>
- Skowron, G., & Ogden, R. C. (2006). *Reverse transcriptase inhibitors in HIV/AIDS therapy*. Humana Press.
- Soriano, V., & Mendoza, C. D. (2002). Genetic mechanisms of resistance to NRTI and NNRTI. *HIV Clinical Trials*, 3(3), 237–248. <https://doi.org/10.1310/06DD-UN4D-9AW2-RLBY>
- Spampinato, S., Marino, A., Celesia, B., Rullo, E., Condorelli, F., Cacopardo, B., & Nunnari, G. (2024). Implications and considerations of V179D mutation in a patient with HIV treated with cabotegravir/rilpivirine: A case report and mini-review of the literature. *World Academy of Sciences Journal*, 6(3), 19. <https://doi.org/10.3892/wasj.2024.234>
- Spampinato, S., Marino, A., Celesia, B., Rullo, E., Condorelli, F., Cacopardo, B., & Nunnari, G. (2024). Implications and considerations of V179D mutation in

- a patient with HIV treated with cabotegravir/rilpivirine: A case report and mini-review of the literature. *World Academy of Sciences Journal*, 6(3), 19. <https://doi.org/10.3892/wasj.2024.234>
- Struck, D., Lawyer, G., Ternes, A.-M., Schmit, J.-C., & Bercoff, D. P. (2014). COMET: Adaptive context-based modeling for ultrafast HIV-1 subtype identification. *Nucleic Acids Research*, 42(18), e144–e144. <https://doi.org/10.1093/nar/gku739>
- Sullivan, A., & Sullivan, A. (2014). *HIV for non-HIV Specialists: Diagnosing the undiagnosed*. Medical Foundation for AIDS & Sexual Health.h.
- Sumantri, R. (2013). Kegagalan Terapi Infeksi HIV/AIDS dan Resistensi Antiretroviral. *Global Medical & Health Communication (GMHC)*, 1(1), pp.31-33.
- Sun, N., & Yau, S. S.-T. (2022). In-depth investigation of the point mutation pattern of HIV-1. *Frontiers in Cellular and Infection Microbiology*, 12, 1033481. <https://doi.org/10.3389/fcimb.2022.1033481>
- Tao, K., Zhou, J., Nagarajan, P., Tzou, P. L., & Shafer, R. W. (2024). Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments. *Antiviral Research*, 230, 105988. <https://doi.org/10.1016/j.antiviral.2024.105988>
- Tseng, A., Foisy, M., & Fletcher, D. (2002). *Handbook of HIV Drug therapy*. Alice Tseng.
- UNAIDS. (2021). *Global HIV & AIDS statistics — Fact sheet*. <https://www.unaids.org/en/resources/fact-sheet>
- Vanangamudi, M., Palaniappan, S., Kathiravan, M. K., & Namasivayam, V. (2023). Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). *Viruses*, 15(10), 1992. <https://doi.org/10.3390/v15101992>
- Widiyanti, M. (2016). Dampak Perpaduan Obat ARV pada Pasien HIV/AIDS ditinjau dari Kenaikan Jumlah Limfosit CD4+ di RSUD Dok II Kota

Jayapura. *JURNAL PLASMA*, 1(2), 53–58.
<https://doi.org/10.22435/plasma.v1i2.4535.53-58>

Widiyanti, M., & Hutapea, H. (2018). Hubungan Jumlah Cluster of Differentiation 4 (CD4) dengan Infeksi Oportunistik Pada Pasien HIV/AIDS di Rumah Sakit Umum Daerah (RSUD) DOK II Jayapura. *JURNAL BIOLOGI PAPUA*, 7(1), 16–21. <https://doi.org/10.31957/jbp.427>

Widiyanti, M., & Sandy, S. (2016). Gambaran Subtipe HIV-1 dengan Kadar CD4, Stadium Klinis, dan Infeksi Oportunistik Penderita HIV/AIDS di Kota dan Kabupaten Jayapura, Papua. *Majalah Kedokteran Bandung*, 48(1), 1–5. <https://doi.org/10.15395/mkb.v48n1.738>

Widiyanti, M., Adiningsih, S., & Kridaningsih, T. N. (2021). Genetic diversity of multiple human immunodeficiency virus-1 (HIV-1) clades in West Papua. *IOP Conference Series: Earth and Environmental Science*, 948(1), 012077. <https://doi.org/10.1088/1755-1315/948/1/012077>

Widiyanti, M., Adiningsih, S., Kridaningsih, T. N., Natalia, E. I., Purba, D. A., Fitriana, E., & Hutapea, H. (2021). Peta Genotyping HIV-1 Papua & Papua Barat.

Widiyanti, M., Fitriana, E., Natalia, E. I., & Wike, I. (2017). Identification Of Antiretroviral Mutation In Protease And Reverse Transcriptase Inhibitor In Human Immunodeficiency Virus-1 Of Hiv/Aids Patients In Mimika Regency, Papua. *Folia Medica Indonesiana*, 53(1), 56. <https://doi.org/10.20473/fmi.v53i1.5491>

Widiyanti, M., Hadi, M. I., Adiningsih, S., Alamudi, M. Y., & Kumalasari, M. L. F. (2019). Karakteristik Demografi ODHA di Papua. *Journal of Health Science and Prevention*, 3(1), 10–15. <https://doi.org/10.29080/jhsp.v3i1.175>

Widiyanti, M., Sandi, S., & Wibowo, H. A. (2018). Analisis Subtipe HIV-1 dan Faktor Penyebarannya pada Penderita HIV di RS. Yowari Kabupaten Jayapura, Papua. *JURNAL BIOLOGI PAPUA*, 6(1), 25–30. <https://doi.org/10.31957/jbp.449>

World Health Organization. (2007). *Antiretrovirals for HIV: a compilation of facts and product information* (No. Technical Publication No. 55). WHO Regional Office for South-East Asia.

Yang, Z., Wei, S., Liu, J., Piao, J., Xu, L., Sun, Y., Deng, X., Yang, X., Liu, C., Ma, S., Zhao, Q., & Huo, Y. (2020). Characterization of HIV-1 subtypes and drug resistance mutations in Henan Province, China (2017–2019). *Archives of Virology*, *165*(6), 1453–1461. <https://doi.org/10.1007/s00705-020-04606-6>

Yousefi, R. (2024). The Molecular Docking of Specific Reverse Transcriptase Inhibitory Ligands onto the Molecular Model of HIV-1 Reverse Transcriptase. *Trends in Pharmaceutical Sciences*, *10*(2). <https://doi.org/10.30476/tips.2024.102488.1239>